
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Calpain 15 CRISPR Activation Plasmid (h) | sc-411016-ACT | 20 µg | $397.00 |
Human CAPN15 encodes calpain 15, an atypical member of the calpain family of calcium-dependent cysteine proteases implicated in regulated proteolysis that shapes protein turnover and signaling outputs. Calpain activity can influence cytoskeletal remodeling, vesicular trafficking, and stress-responsive pathways by limited cleavage of substrates rather than bulk degradation, thereby tuning cellular homeostasis. CAPN15 expression has been studied in the context of tissue development and cell-state regulation, where altered protease signaling may impact differentiation programs and neuronal or epithelial function. Dysregulated calpain-related proteolysis has been linked in the literature to mechanisms relevant to neurodegeneration, inflammation, and cancer-associated signaling, supporting CAPN15 as a target for pathway mapping and functional genomics.
Calpain 15 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CAPN15 expression without altering the underlying DNA sequence.
Calpain 15 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CAPN15 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CAPN15 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Calpain 15 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CAPN15 locus and enabling the study of Calpain 15-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Calpain 15 pathway restoration in tumor cells with silenced or reduced CAPN15 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.